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ABSTRACT
We provide first-time evidence for ERβ-mediated transcriptional upregulation of 
c-FLIP as an underlying mechanism in the development of castrate-resistant cancer. 
While androgens inhibit apoptosis partly through transcriptional upregulation of 
the anti-apoptotic protein, c-FLIP in androgen-responsive cells, they downregulate 
c-FLIP in androgen-independent cells. We found that although Sp1 and p65 trans-
activate c-FLIP, the combination of Sp1 and p65 has differential effects in a cellular 
context-dependent manner. We show that activation of the androgen metabolism 
enzyme, aldo-keto reductase, AKR1C1, relieves androgen independence through 
activation of 3β-Adiol-mediated upregulation of ERβ. ERβ competes with Sp1 and 
Sp3 to transcriptionally downregulate c-FLIP in the absence of consensus estrogen-
response element in androgen-independent cells. Forced expression of AR in androgen-
independent cells show that ERβ-mediated growth inhibition occurs under conditions 
of androgen independence. Reactivation of ERβ with the estrogenic metabolite, 
2-methoxyestradiol, decreased enrichment ratio of Sp1/Sp3 at the c-FLIP promoter 
with concomitant effects on cell growth and death. Expression of Sp1 and c-FLIP 
are elevated while AKR1C1, ERβ and Sp3 are significantly low in human prostate 
tumor samples. ERβ is epigenetically silenced in prostate cancer patients, therefore 
our results suggest that combination of ERβ agonists with ADT would benefit men 
stratified on the basis of high estrogen levels.
INTRODUCTION
The binding of androgens to the androgen receptor 
(AR) plays an important role not only in the growth and 
development of normal prostate, but also in prostatic diseases 
including prostate cancer (PCA). Accordingly, androgen 
deprivation therapy (ADT) is the mainstay therapeutic 
approach for locally advanced PCA [1]. Although initially 
effective, the outcome is transient, invariably resulting 
in progression to aggressive metastatic castrate-resistant 
form (CRPC) with no effective curative options [2]. ADT 
functions by causing apoptotic cell death of cancer cells. 
However, advanced prostate cancer cells develop resistance 
to ADT-induced apoptosis leading to development of 
aggressive castrate-resistant status [3]. Additionally, though 
PCA is an androgen-dependent disease, levels of androgens 
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decrease while estrogens increase with age [4]. Accordingly, 
it was suggested that rather than androgens per se, the 
ratio of androgen to estrogens may be a potential reason 
for development of CRPCA [5]. This is corroborated by 
emerging evidence implicating a role of estrogen receptors 
(ERs) primarily α and β (ERα and β) in prostate cancer cells 
and human prostate tumors [6, 7]. Furthermore, ectopic 
expression of ERβ inhibits growth, migration, invasion 
and epithelial mesenchymal transition of prostate cancer 
cells and ERβ knockout mice develop hyperplasia and 
PIN lesions [7, 8]. However, the underlying mechanism 
of ERβ-mediated prostate pathogenesis including CRPCA 
is undefined. Studies to understand the molecular events 
associated with CRPCA identified an important role for 
the anti-apoptotic FLICE-inhibitory protein (c-FLIP) [11]. 
c-FLIP is aberrantly expressed in high-grade and castrate-
resistant human prostate tumors. Furthermore, nude mice 
implanted with c-FLIP overexpressing LNCaP cells develop 
androgen independent prostate tumors suggesting androgen 
regulation of c-FLIP. Evidence from epidemiological and 
laboratory studies indicate lower PCA incidence in men 
consuming soy products [12]. Gut microbial digestion of 
these products generates estrogenic metabolites with anti-
tumorigenic activity [12]. Along these lines, studies from 
number of laboratories including our own demonstrated anti-
tumorigenic activity for a non-toxic endogenous estrogenic 
metabolite 2-methoxyestradiol (2-ME2) in multiple 
tumor types in vitro and in vivo [13–17]. In addition, 
downregulation of c-FLIP by 2-ME2 has been reported to 
inhibit tumor growth in vitro and in vivo [13–17]. Despite 
the circumstantial evidence, the underlying mechanism 
through which androgens and loss of ERβ influence c-FLIP 
deregulation during prostate carcinogenesis and whether 
2-ME2-mediated inhibition of prostate tumor development 
involves ERβ/c-FLIP remains to be defined.
Here we investigated the functional interaction 
between androgen metabolism-mediated activation of 
ERβ as a possible underlying mechanism involved in 
deregulation of c-FLIP. We provide evidence that c-FLIP is 
negatively regulated by ERβ possibly through modulation 
of Sp1/Sp3 binding to its promoter. We also provide 
evidence that inhibition of Sp1 activation coupled with 
ERβ activation with 2-ME2 suppresses tumor cell growth 
and induces apoptosis. These findings identify ERβ as a 
negative modulator of c-FLIP and suggest strategies to target 
ERβ activation either directly or by enhancing androgen 
metabolism enzyme AKR1C1 along with AR inhibition as a 
novel approach for effective management of CRPCA.
RESULTS
Differential regulation of c-FLIP by Sp1 and 
NFκB in prostate cancer cells
Although published studies have demonstrated 
that 2-ME2 inhibits prostate cancer cell growth by 
suppressing transcriptional activation of c-FLIP, the 
molecular mechanism through which 2-ME2 suppresses 
c-FLIP activation is not defined [13]. Transient expression 
assays using exonuclease deletion constructs spanning 
the 5′-flanking region of c-FLIP promoter element 
identified –121/+242 sequence with maximal constitutive 
reporter activity in both androgen-responsive LNCaP 
and androgen-independent prostate cancer cells PC-3 
and DU145 cells (Fig. 1A-1C). Interestingly, promoter 
activity increased significantly in response to androgens 
(5α-DHT stimulation) in LNCaP cells (Fig. 1C and data 
not shown). Constitutive c-FLIP promoter activity in PC-3 
and DU145 cells or 5α-DHT-stimulated activity in LNCaP 
cells decreased following treatment with 2-ME2. Inclusion 
of sequence elements upstream of –121 not only decreased 
the basal promoter activity but also the 2-ME2 response. 
These data suggest that 2-ME2 response elements are 
located within sequence elements –121/+242 and that this 
sequence element was sufficient to maintain the c-FLIP 
core promoter activity.
Analysis of –121/+242 sequence identified 
putative binding sites for multiple transcription factors 
including AR, Sp1 and NFκB (Supplementary Fig. S1A). 
Therefore, we tested the impact of ectopic expression of 
Sp1, Sp3 and p65 (NFκB) on c-FLIP promoter activity 
using co-transfections. Ectopic expression of Sp1 or 
p65 transactivated c-FLIP in all three prostate cancer 
cell lines (Fig. 1D-1F). The observed p65-mediated 
transactivation was repressed in cells co-transfected 
with phosphorylation defective IκBα indicating the 
specificity of NFκB-mediated effects. Interestingly, we 
observed differential effects of co-transfection with Sp1 
on p65 transactivation of c-FLIP promoter. Sp1 repressed 
p65 transactivation of c-FLIP in DU145 and LNCaP 
cells (Fig. 1E-1F) with no significant effect in PC-3 
cells (Fig. 1D). Furthermore, ectopic expression of Sp3 
or treatment with 2-ME2 inhibited both Sp1 and p65-
mediated transactivation (Fig. 1D-1F). These data suggest 
(i) Sp1 as master regulator of c-FLIP; and (ii) either Sp1 
or p65 can individually transactivate c-FLIP, and that the 
combination of Sp1 and p65 can have differential effects 
depending on the cell type.
Identification and characterization of DNA-
protein complexes binding to c-FLIP promoter
Chromatin immunoprecipitation assay (ChIP) was 
used to examine whether Sp1 regulates endogenous c-FLIP 
in the context of chromatin using overlapping binding sites 
for Sp1 and p65 (Supplementary Fig. S1B). Chromatin 
immunoprecipitated extracts from untreated DU145 but 
not PC-3 cells with anti-Sp1 antibody amplified c-FLIP 
sequence (Fig. 2A and 2B). It is noteworthy to mention 
here that Sp1 was recruited to the c-FLIP sequences 
upstream of –833 (data not shown). In contrast, in LNCaP 
cells significant enrichment of Sp1 was observed only 
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under androgen-stimulated conditions (Fig. 2C). Treatment 
with 2-ME2 reduced Sp1 but enhanced Sp3 enrichment in 
DU145 cells with no significant effect in LNCaP cells. No 
significant change in binding to β-actin (negative control) 
was observed under these conditions. It should be noted 
that in transient expression assays Sp1 transactivates 
c-FLIP promoter in PC-3 cells. These surprising findings 
lead us to examine p65 binding (given its overlap with 
Figure 1: Identification of core c-FLIP promoter elements sufficient for constitutive and 2-ME
2
 response, and regulation 
of c-FLIP with multiple transcription factors including Sp1, Sp3 and NFκB. A–C. Androgen independent PC-3, DU145, 
and androgen-responsive LNCaP cells were transfected with indicated deletion constructs of c-FLIP reporter plasmid (0.5 μg). Post-
transfection, cells were treated with 2-ME2 (3 μM for LNCaP and PC-3, and 5 μM for DU145) for 24 h. Luciferase activity was measured. 
Cells transfected with pGL3 empty vector was used as negative control. Data presented is average ± S.E.M of three independent experiments 
conducted in triplicate. *p < 0.05. D–F. PC-3, DU145 and LNCaP cells were co-transfected with pGL3-FLIP (–121/+242)-Luc plasmid 
along with empty vector (pCMV3.1) or expression plasmids for (pCMV-Sp1, pCMV-Sp3, pCMV-p65 or IκBα mutant, a super repressor 
of NFκB (0.5 μg/well of each). Post-transfection, cells were treated with 2-ME2 for 24 h and luciferase activity was measured. Cells 
transfected with empty vector was used as negative control. Data presented is average ± S.E.M of three independent experiments conducted 
in triplicate.
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Sp1 site) to endogenous c-FLIP. Interestingly, chromatin 
immunoprecipitated extracts with anti-p65 specifically 
bound these sequences that was abolished with 2-ME2 in 
PC-3 cells (Fig. 2B). Taken together, these data suggest 
multiple transcription factors including Sp1, Sp3 and 
NFκB differentially regulate c-FLIP depending on the cell 
type and recruitment of both Sp1 and p65 to overlapping 
sites of c-FLIP promoter.
To examine if Sp1 and p65 regulate c-FLIP by 
binding to the same sequence elements, gel super-shift 
experiments were conducted using c-FLIP promoter 
sequence (+64/+89 containing AR, Sp1 and NFκB 
overlapping bindings sites; Supplementary Fig. S1C) as 
radiolabeled probe. Given our data suggesting differential 
regulation of c-FLIP between LNCaP and DU145 
vs. PC-3, we performed gel shift experiments using 
LNCaP and PC-3 cells. Nuclear extracts from PC-3 or 
5α-DHT-stimulated LNCaP cells formed three distinct 
DNA-protein complexes (Complex I, II and III; Fig. 2D 
and 2E). The observed complexes were either completely 
(CI and II) or partially (CIII) abolished in response to 
2-ME2 treatment (lane 3). Competition experiments 
using c-FLIP oligo or mutant Sp1 oligonucleotide as 
homologous or heterologous competitors respectively 
abolished both CI and II but CIII was partially abolished 
(lanes 4 and 5). These data suggest the presence of Sp1, 
Sp-related and factors other than Sp1 in these complexes. 
Pre-incubation of nuclear extracts with antibodies against 
Sp1 and Sp3 showed super-shifted complexes (lanes 
6 and 7; indicated as SS) or reduced complex formation 
with p65 and p50 (lanes 8 and 9) in both cell types. In 
addition, pre-incubation of nuclear extracts from LNCaP 
cells with AR antibody partially abolished the observed 
DNA-protein complex indicating the presence of AR in 
androgen-responsive cells (lane 5a).
Previous studies have demonstrated the presence 
of androgen response element (ARE)-1 within this 
sequence [20]. These data prompted us to perform gel shift 
experiments using c-FLIP sequence containing wild type 
ARE-1 (Supplementary Fig. S1D). 5α-DHT-stimulated 
Figure 2: Sp1, Sp3 and NFκB bind to the endogenous c-FLIP promoter. A. DU145 cells were untreated or treated with 2-ME2 
(5 μM) for 24 h, and chromatin immunoprecipitation quantitative real-time PCR (ChIP-qPCR) was performed using anti-Sp1 or anti-Sp3 
antibody. The amplification value from immunoprecipitated DNA was normalized to 10% input. Error bars indicate ± S.E.M. (n = 3). 
*p < 0.05. B. PC-3 cells were untreated or treated with 2-ME2 (5 μM) for 24 h. C. LNCaP cells were untreated or treated with 2-ME2 
(3 μM) for 6 h in the presence or absence of DHT (1 nM). Gel-based ChIP-PCR was performed using anti-Sp1 or anti-p65 antibody. 
D. Binding of AR, Sp1, Sp3 and p65 to the c-FLIP promoter sequence elements containing Sp1, NFκB, or AR binding sites to nuclear 
extracts prepared from PC-3 cells using electrophoretic mobility shift assay (EMSA). PC-3 cells untreated or treated with 2-ME2 (3 μM) 
for 24 h. Radiolabeled c-FLIP probe was preincubated with 100-fold molar excess of unlabeled c-FLIP sequence (homologous) or Sp1 
oligonucleotide with mutation (heterologous) for 5 min prior to incubation with nuclear extracts. Nuclear extracts pre-incubated with 
indicated antibodies for 30 minutes on ice were used in super-shift experiments. E. Nuclear extracts prepared from LNCaP cells untreated or 
pretreated with 2-ME2 (3 μM) for 6 h prior to stimulation with DHT (1 nM) for 1 h were used in EMSA. EMSA was carried out essentially 
as described above. F. Binding of nuclear extracts from untreated or 5α-DHT stimulated LNCaP cells to c-FLIP ARE-1 (+57/+71) as 
radiolabeled probe was shown. (CI-III: DNA-protein complexes, UB: unbound free probe, SS: super-shifted bands).
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nuclear extracts from LNCaP cells showed enhanced 
binding to this sequence that was reduced in response to 
2-ME2 (lanes 3 and 4; Fig. 2F). Competition experiments 
using ARE1 with mutation in conserved binding site 
eliminated the observed DNA-protein complex indicating 
the presence of factors other than AR, including Sp1 and 
p65 (lane 5; Fig. 2F). Taken together, these data show 
the presence of AR, Sp1 and p65 in CI and Sp3 in CII 
and suggest that AR bound c-FLIP promoter sequence 
containing Sp1/NFκB sequences is upregulated in 
response to androgens in LNCaP cells.
Androgen down regulate c-FLIP activation in 
androgen independent cells
These results prompted us to examine if Sp1/p65 can 
mediate androgen regulation of c-FLIP in the absence of 
AR using AR-negative DU145 cells. Surprisingly, c-FLIP 
promoter activity was significantly decreased in response 
to 5α-DHT in these cells (lane 3; Fig. 3A). Consistent 
with data presented in Fig. 1B, 2-ME2 further reduced the 
observed basal and 5α-DHT-inhibited c-FLIP promoter 
activity (lanes 2 and 4; Fig. 3A). This unexpected finding 
prompted us to test if the detected 5α-DHT-mediated 
effects are related to its metabolism. Therefore, we 
conducted these experiments using non-metabolizable 
androgen R1881. Interestingly, R1881 had no significant 
effect on c-FLIP activation, albeit 2-ME2 decreased (lanes 
5 and 6; Fig. 3A). Next we investigated if the observed 
5α-DHT-mediated decrease in c-FLIP activation is related 
to reduced Sp1 enrichment at the promoter. ChIP analysis 
showed significant enrichment of Sp3 and non-significant 
increase in Sp1 (relative to control IgG antibody) at the 
endogenous c-FLIP promoter in response to 5α-DHT 
but not R1881 treatment (lanes 2&7 and 4&9; Fig. 3B). 
Remarkably, 2-ME2-treatment showed 10-fold higher 
enrichment of Sp3 (relative to control IgG antibody) to 
the endogenous c-FLIP promoter following 5α-DHT-
stimulation (lane 8; Fig. 3B). These results suggest that 
5α-DHT metabolic products could be involved in the 
observed 5α-DHT-induced downregulation of c-FLIP.
Aldo-keto reductase, AKR1C1 predominantly 
metabolizes 5α-DHT into 3β-Adiol, a physiological 
ligand for ERβ [21]. We examined alterations in the 
expression of AKR1C1 and ERβ in DU145 cells and 
found that 5α-DHT and 2-ME2 significantly up-regulated 
mRNA expression of AKR1C1 and ERβ (Fig. 3C). These 
correlative results led us to hypothesize that metabolic 
inactivation of 5α-DHT by AKR1C1 could produce 
3β-Adiol that in turn reduces c-FLIP transcriptional 
activation via ERβ activation. To directly test this, we 
examined c-FLIP transactivation by ectopically expressing 
ERβ or pharmacologically by treating cells with 3β-Adiol. 
Ectopic expression of ERβ (left panel) or treatment with 
3β-Adiol (right panel) decreased c-FLIP promoter activity 
significantly (Fig. 3D). Similar results were also obtained 
with PC-3 cells (Fig. 3E). In contrast, 3β-Adiol but not 
ERβ decreased c-FLIP promoter activity in LNCaP cells 
(Fig. 3E bottom panel). Given the differential status of AR 
between LNCaP and PC3 & DU145 cells, we reasoned 
that the presence of AR could be a contributing factor 
for the observed differential regulation of c-FLIP by 
ERβ. To address this, we performed similar experiments 
using PC-3 cells stably overexpressing AR (PC-3 AR). 
Intriguingly, we did not observe ERβ-mediated down 
regulation of c-FLIP promoter activity in these cells 
(Fig. 3F). These data suggest that metabolic inactivation 
of 5α-DHT by AKR1C1 could produce 3β-Adiol, which 
in turn reduces c-FLIP transcriptional activation possibly 
via ERβ activation. Furthermore, AR inhibits ERβ-
mediated inhibition of c-FLIP activation. Given the lack 
of consensus estrogen response element in the c-FLIP 
promoter, how ERβ suppresses c-FLIP is unclear.
ERβ competes with Sp1 and Sp3 for binding to 
c-FLIP promoter
Previous studies have shown that estrogen receptors 
can regulate gene expression non-genomically through 
interactions with other transcription factors such as Sp1 
[22, 23]. We tested this hypothesis using co-transfection 
assays in DU145 cells. Consistent with data presented 
in Figs. 1E and 3D; ectopic expression of Sp1 trans- 
activated while Sp3 trans-repressed Sp1-mediated 
activation (lanes 2 and 3; Fig. 4A). On the other hand, 
ectopic ERβ expression not only suppressed constitutive & 
Sp1-mediated activation but also Sp3-mediated inhibition 
c-FLIP activation (lanes 4–7; Fig. 4A). Furthermore, 
ectopic ERβ expression further suppressed Sp3-mediated 
inhibition of Sp1 transactivation (lane 8; Fig. 4A). 
Although the biological significance of these observations 
is unclear, these results imply that ERβ suppresses c-FLIP 
transcriptional activity possibly by competing with Sp1 
and Sp3. Biological relevance of 5α-DHT or 2-ME2-
mediated suppression of c-FLIP activation was determined 
by examining the effect of 5α-DHT on cell growth 
and apoptosis in the presence and absence of 2-ME2. 
Treatment with 5α-DHT significantly decreased colony-
forming ability of DU145 cells. Decreased colony forming 
ability was further reduced in the presence of 2-ME2 
(Fig. 4B). Immunoblot analysis revealed dose-dependent 
increase in PARP cleavage and decreased FLIPL (Fig. 4C). 
These observations suggest that ERβ can inhibit growth 
of androgen-independent prostate cancer cells through 
transcriptional downregulation of c-FLIP and activation 
of apoptosis.
We analyzed the expression of Sp1 and Sp3 
in human prostate tissues by immunohistochemistry 
(IHC). IHC analysis revealed significantly elevated Sp1 
expression (27/35 human prostate tumors; p = 0.035) with 
no detectable expression in the normal tissue (Fig.  5A 
and Table 1). However, differences in Sp3 expression 
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Figure 3: Androgen metabolism regulates c-FLIP transcriptional activity. A. 5α-DHT but not R1881 inhibits c-FLIP promoter 
activity. DU145 cells were transfected with c-FLIP reporter plasmid (0.5 μg). Post-transfection, cells were serum-starved for additional 24 h, 
treated with 2-ME2 (5 μM) for 24 h and then stimulated with 5α-DHT or R1881 (1 nM) for 1 h. Luciferase activity was determined. Error 
bars represent ± S.E.M (n = 3). *p < 0.05 (Student’s t-test). B. Binding of Sp1 and Sp3 to the endogenous c-FLIP promoter stimulated with 
DHT or R1881 in the presence or absence of 2-ME2. After stimulation with 5α-DHT or R1881 (1 nM) for 1 h and/or treatment with 2-ME2 
for 24 h, ChIP-qPCR was performed using anti-Sp1 or anti-Sp3 antibody in DU145 cells. The amplification value from immunoprecipitated 
DNA was normalized to 10% input. Error bars represent ± S.E.M. (n = 3). *p < 0.05. C. AKR1C1 and ERβ mRNA expression in DU145 
cells treated with 5α-DHT or 2-ME2. Total RNA was isolated from cells treated with 5α-DHT or R1881 (1 nM) for 1 h, or with 2-ME2 
(5 μM) for 24 h. PCR reactions were conducted in triplicate, and relative mRNA expression was normalized to β-actin. Error bars represent 
± S.D. (n = 3). *p < 0.05. D–F. ERβ regulates c-FLIP in prostate cancer cells. pGL3-FLIP (–121/+242)-Luc plasmid was co-transfected 
along with empty vector (pSDM101) or expression plasmids for ERβ (0.5 μg/well). Post-transfection, cells were treated with 2-ME2 for 
24 h and luciferase activity was measured. In addition, cells were transfected with pGL3-FLIP (–121/+242)-Luc plasmid and treated with 
different concentration of 3β-Adiol. Panels D, E, and F represent DU145, PC-3 (Fig. 3E top panel), LNCaP (Fig. 3E bottom panel) and PC-3 
AR (PC-3 cells stably expressing AR) cells respectively. Data presented is average ± S.E.M of three independent experiments conducted 
in triplicate. *p < 0.05.
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did not reach statistical significance (Table 1). We also 
compared the expression of AKR1C1, c-FLIP, Sp1, Sp3 
and ERβ in human prostate tumors and normal tissue from 
oncomine, cancer-profiling database. In silico analysis of 
these data from two different cohorts revealed significantly 
upregulated expression of Sp1 and c-FLIP in human 
prostate tumors compared to normal tissue (Fig. 5B). On 
the other hand, expression of AKR1C1, ERβ and Sp3 was 
down regulated (Fig. 5C).
DISCUSSION
Recent evidence shows the importance of androgen 
metabolism in the progression of prostate cancer to 
castrate-resistant state. Here, we show for the first time 
that AKR1C1 can contribute to CRPCA by inhibiting 
apoptosis through ERβ-mediated transcriptional 
suppression of c-FLIP. The tumor suppressive role for 
ERβ has been reported using in vitro cell culture and 
in vivo animal models [6–10]. It has also been reported 
that human prostate cancer cells express both ERα and 
β and ERβ knockout mice develop HGPIN lesions [9]. 
Furthermore, in silico analysis revealed significantly 
decreased expression of both AKR1C1 and ERβ in human 
prostate tumors compared to normal tissue. Therefore, our 
data demonstrating tumor suppressor role for ERβ is in 
agreement with these published findings.
Additionally, we provide evidence that ERβ inhibits 
apoptosis non-genomically by competing with Sp1 and Sp3 
to transcriptionally downregulate c-FLIP. Given the lack 
of understanding how ERβ activation inhibits apoptosis to 
drive prostate pathogenesis, our observations are novel. 
Estrogen receptors (ERs) regulate gene expression either 
classically by binding to estrogen response element (ERE) 
in the promoter regions or non-classically in association 
with other transcription factors including AP-1, Sp1 
and NFκB [22]. Genome-wide global profiling of ERβ 
occupancy studies indicate that ERE is not the major 
binding site for ERβ, but it can bind to sites including Sp1 
[23]. Data presented in this manuscript provide evidence 
that 2-ME2 (i) inhibits Sp1 transactivation of c-FLIP; (ii) 
activates ERβ in a dose-dependent manner and (iii) that 
ectopic expression of ERβ or treatment with its ligand 
3β-Adiol suppresses c-FLIP promoter activity despite 
lack of consensus ERE. The observed downregulation 
of c-FLIP is associated with induction of apoptosis in 
prostate cancer cells. Based on these observations, we 
speculate that ERβ downregulates c-FLIP either directly 
by binding to Sp1 sites on the c-FLIP promoter or by 
modulating the ratio of Sp1/Sp3 through competitive 
Figure 4: Non-genomic regulation of c-FLIP by ERβ. A. ERβ suppresses Sp1 and Sp3-mediated transactivation of c-FLIP in 
DU145 cells. Transient expression was conducted as described in materials and method using pGL3-FLIP (–121/+242)-Luc plasmid in the 
presence and absence of expression plasmids for Sp1, Sp3 or ERβ. Where indicated cells were co-transfected with expression plasmids 
for Sp1, Sp3 or ERβ or all three (0.5 μg/well of each) and total amount of DNA was maintained constant using pcDNA3.1. (*p < 0.05; 
*compared to pSDM101 control, °compared to Sp1, and ^compared to Sp3). B. Colony forming ability of DU145 cells stimulated with 
5α-DHT. DU145 cells were seeded in 24-well plates at a density of 100 cells per well in triplicate in 1 mL of growth media and stained 
with crystal violet after treating with 5α-DHT (1 nM) for 1 h and 2-ME2 for 24 h (Left), and colonies were counted (Right). Error bars 
indicate ± S.D. (n = 3). C. 2-ME2 induces apoptosis in DU145 cells. Whole cell extracts prepared from cells treated with increasing 
concentration of 2-ME2 (1, 5, and 10 μM) were used in immunoblotting with antibodies for cleaved PARP (48 h) and FLIPL (12 h). β-actin 
was used as a loading control. Numbers indicate ratio of c-FLIP or c-PARP with respect to β-actin loading control.
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DNA binding. Alternatively, involvement of other ERβ 
coregulators cannot be ruled out. Additionally, it is also 
possible that 2-ME2-treatment can activate epigenetically 
silenced ERβ through demethylation. It has been reported 
that due to methylation of the ERβ promoter, relative 
ERβ expression is undetectable in LNCaP and very low 
in DU145 cells compared to PC-3 cells [26]. Since our 
results show that treatment with 2-ME2 resulted in dose-
dependent increased ERβ expression in DU145 cells they 
signify the possibility that 2-ME2-treatment can activate 
epigenetically silenced ERβ through demethylation, which 
will be a focus of our future studies. Taken together, these 
observations for the first time suggest that loss of ERβ can 
contribute to aggressive advanced prostate cancer through 
transcriptional regulation of c-FLIP.
Sp1 and NFκB are transcription factors that regulate 
expression of genes involved in various cellular processes 
of oncogenesis including differentiation, apoptosis, cell 
migration, and cell cycle progression [27, 28]. Moreover, 
published studies show correlation between elevated 
levels of NFκB in castrate-resistant prostate tumors and 
disease progression [29]. However, to the best of our 
Figure 5: Expression of Sp1, Sp3, c-FLIP, AKR1C1 and ERβ in human prostate tumors. A. Human prostate tissue array 
containing 80 tissue cores (duplicated tissues from 40 individual donors) obtained from Cybridi, Inc. was used in immunohistochemical 
evaluation using antibodies against Sp1, Sp3 (sc-28305) and negative control IgG. Representative picture at different magnifications is 
shown. B. Box plots of in silico analysis of expression of Sp1 (left panels) and c-FLIP (right panels) in human prostate cancer and 
normal prostate tissues. Oncomine microarray data retrieved from two independent cohorts was used. C. Box plots of in silico analysis 
of expression of AKR1C1, ERβ and Sp3 expression (left, middle and right panels) in human prostate cancer and normal prostate tissues. 
(NPG: normal prostate gland, PC: prostate carcinoma).
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knowledge no studies have examined the expression of 
Sp1 and Sp3 in human prostate tumors. The current study 
for the first time demonstrates elevated expression of Sp1 
in human prostate tumors compared to normal tissue. 
These observations are consistent with published studies 
in other tumor types [30–32]. For example, in comparison 
to normal tissues or cells Sp1 levels are higher in breast, 
thyroid, hepatocellular, pancreatic, colorectal, gastric and 
lung cancer. In addition, abnormal Sp1 levels are highly 
correlated with stage and poor prognosis of cancer [31].
Our data also shows potential combinatorial effects 
of Sp1 with AR, Sp3 and p65 in the regulation of c-FLIP 
transcription. Treatment with pro-apoptotic agent 2-ME2 
also blocked the observed effects. Sp1 and Sp3 both 
bind GC-rich sequences and regulate gene expression 
either thorough cooperative interactions or inhibitory 
interactions whereby Sp3 can decrease Sp1 transactivation. 
Furthermore, published evidence demonstrates that Sp1 
can also regulate gene expression in association with 
ligand activated and orphan nuclear receptors including 
AR, ER, progesterone receptor (PR) and retinoic acid 
receptor (RAR). Sp1 and/or Sp3 also cooperatively 
activate gene expression through interaction with other 
transcription factors including E2F, SMADs, NFκB, 
GATA and c-Jun [28]. Previous studies have demonstrated 
association between Sp1 and AR. For example, it has 
been shown that despite lack of consensus ARE, AR can 
transactivate p21 by binding to Sp1 sequence elements 
in association with Sp1 in response to androgens [33]. In 
addition, Sp1 stimulates AR target gene PSA through its 
transcriptional activation ability. Inhibition or knocking 
down of Sp1 to normal cellular level has been reported to 
decrease tumor formation, growth and metastasis [34–37]. 
For example, chemopreventive agents including Betulinic 
acid and Curcumin reduce the expression of Sp1 and 
Sp3 with consequent reduced expression of their target 
genes including EGFR, Cyclin D1, VEGF and SREB2. 
Mithramycin A and tolfenamic acid together reduce 
Sp1 levels in pancreatic cancer cells. Thus, interactions 
between Sp1 and other proteins can differentially affect 
Sp1-dependent transactivation depending on the promoter 
context [27, 28]. In agreement with these published 
findings, our work demonstrates that 2-ME2-mediated 
restoration of ERβ prevents Sp1 or p65 recruitment or 
combination of both Sp1 and p65 to c-FLIP promoter 
with consequent induction of apoptosis. In future studies, 
we will determine whether binding of Sp1 facilitates 
recruitment of NFκB or vice versa.
Surprisingly, the current study also observed that 
treatment with metabolizable androgens such as 5α-DHT 
but not non-metabolizable R1881 lowers enrichment 
of Sp1 and increase enrichment of Sp3 to the c-FLIP 
promoter leading to reduced transcriptional activation 
and inhibition of colony formation in DU145 cells. 
How might treatment with 5α-DHT in AR negative 
cells contribute to growth suppression? AKR family 
members including AKR1C1, C2 and C3 function as 
3-, 17- and 20-ketoseteroid reductases respectively to 
form 3-α/β, 17-β and 20-α-hydroxyl metabolites [21, 38]. 
For example, inactivation of 5α-DHT by AKR1C1 results 
in the formation of 3β-Adiol, a potent ERβ ligand [21]. 
Interestingly, the intraprostatic levels of 3β-Adiol, was 
reported to be 100-fold higher than estradiol [21]. Data 
presented here shows (i) expression of AKR1C1 decreases 
in human prostate tumors, (ii) 5α-DHT enhances AKR1C1 
expression; (iii) both 3β-Adiol and ERβ suppress c-FLIP 
activation in DU145 and PC-3 cells but not in LNCaP 
cells. It is noteworthy to mention that PC-3 cells are 
more sensitive to 3β-Adiol, which could be related to 
relatively higher expression of ERβ as it is unmethylated. 
These observations are consistent with the hypothesis 
that variations in the intraprostatic levels of 3β-Adiol 
Table 1: Quantitative analysis of immunohistochemical evaluation of Sp1 and Sp3. 
Immunohistochemical staining was performed essentially as described in methods. The staining results 
were scored blindly and semi quantitatively based on staining intensities and proportion of positive 
staining tumor cells. Briefly, the proportion of positive tumor cells was scored as follows: 0, no stained 
cells; 1, 1–50%; 2, 50–100% positive staining. The intensity score represents the average staining intensity 
of tumor cells: +, mild; ++, weak; +++, strong intensity. The statistical significance was calculated using 
Pearson Chi-Square test. 
Negative Positive Total Pearson Chi-Square
Normal Sp1 3 0 3
Value 7.995 p = 0.035Carcinoma 8 27 35
Total 11 27 38
Normal Sp3 0 0 0
Value 1.327 p = 0.249Carcinoma 23 11 34
Total 23 11 34
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can potentially dictate the outcome of AR/ER signaling 
and possibly the disparate increased risk of CRPCA by 
preventing apoptosis via c-FLIP. Hypothetical model is 
shown in Fig. 6. In future studies, we will determine the 
crosstalk between ERβ and androgen metabolism and 
how other nuclear receptors including ERα impact the 
biological outcome.
Prostate cancer is the second leading cause of cancer 
related deaths in men. Localized cancer can be treated 
effectively either by surgery or radiation [39]. The first 
line therapy, ADT though initially effective, progresses 
to castrate-resistant disease in a majority of patients [40]. 
There are no effective curative approaches for treatment 
of castrate-resistant disease. It is well accepted that AR 
is activated in about 80% of castrate-resistant tumors 
[41]. Several mechanisms including AR amplification/
overexpression, alteration in cofactors or AR variants 
and crosstalk with signal transduction pathways plays a 
critical role in the reactivation of AR [42, 43]. In addition, 
emerging evidence demonstrates survival benefit and tumor 
growth inhibition in patients by suppression of adrenal 
androgen production by abiraterone acetate suggests a 
pivotal role for intratumoral androgen metabolism [44]. 
Similarly, enzalutamide, which provides survival benefit 
directly, inhibits AR activation [45]. Although these data 
provide convincing evidence that androgen metabolism and 
AR are critical targets for CRPC progression, resistance 
to these agents is a major challenge for management of 
CRPC. This is substantiated by recent data demonstrating 
reactivation of glucocorticoid receptor (GR) as a prevalent 
mechanism of acquired resistance to enzalutamide [46]. 
Data presented in this manuscript provided evidence for 
targeting c-FLIP either by increasing the levels of AKR1C1 
or activating ERβ could have therapeutic potential. Do 
changes in AKR1C1 lead to increase in c-FLIP expression 
during CRPCA progression? How do interactions among 
transcription factors Sp1/Sp3/NFκB/AR involved in 
upregulation of c-FLIP contribute to CRPCA? Taken 
together, these observations clearly indicate a conjectural 
role for AKR1C1/ERβ/c-FLIP in prostate pathogenesis 
that warrants additional investigations to elucidate the 
regulation of c-FLIP with respect to androgen metabolism 
and progression to CRPC. Furthermore, despite its ability 
to exert anti-neoplastic activity in variety of tumor types, 
2-ME2 was found to be clinically non-viable [47]. The 
data presented in this manuscript justifies investigations 
combining 2-ME2 with ERβ agonists or 3β-Adiol for 
effective management of CRPC.
MATERIALS AND METHODS
Cell lines and reagents
AR-positive androgen dependent (LNCaP), AR-
negative androgen independent (PC-3 and DU145) human 
prostate cancer cells were purchased from American Type 
Figure 6: Hypothetical model. Hypothetical model of ERβ-mediated transcriptional inhibition of c-FLIP. AKRC1 mediated inactivation 
of 5α-DHT generates 3-β-Adiol, a potent ligand for ERβ. Activation of ERβ by 3-β-Adiol down regulates c-FLIP transcriptionally possibly 
by regulating the binding of Sp and NFκB factors to the c-FLIP promoter. Furthermore, 5α-DHT-induced activation of AR could potentially 
suppress ERβ-mediated transcriptional suppression of c-FLIP activation.
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Culture Collection (Manassas, VA); and AR-positive 
androgen independent (C4-2B) were obtained from 
Dr. Thambi Dorai (Department of Biochemistry and 
Molecular Biology, New York Medical College, NY). All 
cells were grown essentially as described previously [18]. 
Logarithmically growing LNCaP, PC-3 and C4-2B 
(3 μM) and DU145 (5 μM) cells were treated with 
2-methoxyestradiol {2-ME2; obtained from Sigma-Aldrich 
(St. Louis, MO)}.
Western blot analysis and quantitative real 
time PCR
Western blot and qRT-PCR analysis was conducted 
as described previously [18]. Primary antibodies used 
include FLIPL (generated in-house), Cleaved PARP 
(9541S; Cell signaling, Danvers, MA), and β-actin 
(A5316; Sigma-Aldrich, St. Louis, MO). Bound antibody 
was visualized using ECL kit (Thermo Fisher Scientific, 
Waltham, MA). All the blots were stripped and reprobed 
with β-actin to ensure equal loading of protein. Images 
were captured and analyzed using Gene snap software 
(Syngene, Frederick, MD), and quantification was carried 
out using Gene tools software (Syngene, Frederick, MD).
Total cellular RNA isolated using Trizol 
reagent (Invitrogen, Grand Island, NY) according 
to the manufacturer’s instructions. Target genes 
were amplified and expression was measured using 
7300 Applied Biosystems with SYBR Green dye. 
The primers used were as follows: β-actin, forward 
5′-GGCACCCAGCACAATGAAGATCA-A-3′ and reverse 
5′-TAGAAGC-ATTTGCGGTGGACGATG-3′; AKR1C1, 
forward 5′-GCTTTAGAGGCCACCAA-ATTGGCA-3′ 
and reverse 5′-ACTGCCATCTGCAATCTTGCTTCG-3′; 
ERβ, forward 5′-GGCACCTTTCTCCTT-TAGTG-3′ 
and reverse 5′-GGTGTGTTCTAGCGATCTTG-3′. PCR 
reactions were conducted in triplicate, and relative mRNA 
expression was normalized to β-actin. Fold change in 
experiments was determined relative to solvent control 
group. Specific amplification of target genes was validated 
using a dissociation curve.
Transient transfection
For transfections, human prostate cancer cells 
were plated in triplicate at a density of 100,000 cells 
per well in 24-well plates. Cells were transfected with 
indicated c-FLIP reporter plasmids (0.5 μg) along with 
Renilla luciferase (10 ng) using Lipofectamine 2000 
reagent (Invitrogen, Grand Island, NY) according to the 
manufacturer’s recommendations. For co-transfection 
experiments, 0.5 μg/well of Sp1, Sp3, and/or ERβ was 
used along with –121/+242 sequence of c-FLIP reporter 
plasmid. Total amount of DNA was maintained constant 
using backbone vector pcDNA3.1. Where necessary, cells 
were treated with or without 2-ME2 for 24 h and luciferase 
activity was determined using Dual Luciferase Reporter 
Assay system (Promega, Madison, WI).
Electrophoretic mobility shift assay (EMSA) and 
chromatin immunoprecipitation (ChIP)
EMSA and ChIP were essentially conducted as 
described previously [13, 19]. For EMSA, Nuclear 
extracts prepared from LNCaP, C4-2B, and PC-3 
cells treated with 2-ME2 for 24 h were used in EMSA 
experiments using 32P-labeled c-FLIP promoter sequence 
oligonucleotide (+64/+89) containing overlapping 
binding sites for Sp1, Sp3, p65 and AR. For competition 
experiments, the radiolabeled probe was mixed with 100-
fold molar excess of unlabeled double-stranded synthetic 
c-FLIP oligonucleotide for 5 min prior to the addition 
of nuclear extracts. For super-shift experiments, nuclear 
extracts were pre-incubated with Sp1, Sp3, p65, p50, AR 
or control IgG antibodies for 30 min on ice prior to use 
in EMSA. For ChIP, sheared, cross-linked protein-DNA 
fragments were immunoprecipitated with normal rabbit 
IgG (sc-2027), anti-Sp1 (sc-59 X) anti-Sp3 (sc-644 X) 
antibody, or anti-p65 antibody (sc-372 X; obtained from 
Santa Cruz Biotechnology, Santa Cruz, CA) and immune 
complexes were absorbed with protein G magnetic beads 
(Active Motif, Carlsbad, CA). 10% of the input extract 
was saved as input control for normalization before adding 
antibody for immunoprecipitation. Cross-linking was then 
reversed, and immunoprecipitated DNA was amplified by 
PCR or quantitative PCR. PCR products were resolved 
on 3% agarose gel. Densitometry was used to quantify 
the PCR products and the results were normalized 
to respective input values. For qPCR, triplicate PCR 
reactions were performed for each sample and the data 
are presented as the average ± S.E.M. and the results were 
normalized to respective input values. Fold enrichment 
was calculated as 100*2−(Ct[Target]−Ct[Input]).
Clonogenic cell survival assay
For colony formation, DU145 cells seeded in 
24-well plates at a density of 100 cells per well in 1 ml of 
media were treated with 2-ME2 for 24 h in the presence 
or absence of DHT (1 nM towards final 1 h of 24 h 
treatment). Following this treatment, cells were washed 
with PBS and media was replaced with fresh media with 
no treatment. Following one week, cells were fixed with 
ice-cold 100% methanol and stained with 0.5% crystal 
violet in 20% methanol, and groups in excess of 15 cells 
were counted as colonies.
Immunohistochemical evaluation of Sp1 and Sp3 
in human prostate tumors
Human prostate tissue array containing 
80 tissue cores (duplicated tissues from 40 individual 
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donors) obtained from Cybridi, Inc. was used 
in immunohistochemical evaluation. Antibodies 
for Sp1 (sc-59) and Sp3 (sc-28305) and negative 
control IgG antibody obtained from (Santa Cruz 
Biotechnology, Santa Cruz, CA) and (Southern 
Biotechnology, Cat# 0111-01) respectively were used in 
immunohistochemical evaluation. Immunohistochemical 
staining and evaluation was performed by Cybridi, 
Inc. The staining results were scored blinded and 
semi quantitatively based on staining intensities and 
proportion of positive staining tumor cells. Briefly, the 
proportion of positive tumor cells was scored as follows: 
0, no stained cells; 1, 1–50%; 2, 50–100% positive 
staining. The intensity score represents the average 
staining intensity of tumor cells: +, mild; ++, weak; 
+++, strong intensity. The statistical significance was 
calculated using Pearson Chi-Square test.
Oncomine data
Sp1, Sp3, c-FLIP, ERβ, and AKR1C1 expression 
in normal prostate gland and prostate carcinoma 
were obtained from two independent studies for each 
gene expression in the Oncomine database. Primary 
sources are from different group’s microarray data 
mentioned in the graph (http://www.oncomine.org). 
Data sets are log transformed and illustrated as median 
centered box plots between the differences of mRNA 
transcription within cohorts. Statistical significance was 
determined by a two-tailed Mann-Whitney test. Detailed 
information of the standardized normalization and 
statistical calculations are indicated on the Oncomine 
website.
Statistical analysis
All numerical results are expressed as mean ± S.D. 
or S.E.M. derived from 3 independent experiments, unless 
otherwise stated. Statistical analyses were conducted using 
Student’s t-test and statistically significant differences 
were established as p < 0.05. The statistical significance 
of IHC data was calculated using Pearson Chi-Square test.
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